Aeglea BioTherapeutics Holdings has completed a $12 million round of funding to pay for research into engineer enzymes that degrade amino acids present in cancerous tumors. CEO David Lowe told the Austin Business Journal that the Austin biotech company is partnering with University of Texas researcher George Georgiou on a way to administer the treatment intravenously to increase its effectiveness. The company has two employees and is operating out of the Austin Technology Incubator but has plans to move and hire more staff later this year, Lowe said.
Help employers find you! Check out all the jobs and post your resume.
